Article Details
Retrieved on: 2024-01-18 16:52:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The company sold 5% royalties on sales of its drug acoramidis in exchange for $500 million upon FDA approval of the transthyretin amyloidosis ...
Article found on: www.biopharmadive.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here